Company Filing History:
Years Active: 2020
Title: The Innovations of Shao-Chun Chang
Introduction
Shao-Chun Chang is a notable inventor based in Carmel, IN (US). He has made significant contributions to the field of medical research, particularly in the treatment of hepatocellular carcinoma (HCC). His work focuses on innovative therapies that target specific receptors involved in cancer progression.
Latest Patents
Shao-Chun Chang holds a patent for an "Anti-VEGFR2 antibody therapy for hepatocellular carcinoma." This invention provides a human antibody that binds to the human vascular endothelial growth factor receptor 2, specifically ramucirumab. The therapy is designed for the treatment of HCC in patients with alpha-fetoprotein (AFP) levels of 1.5×ULN (Upper Limit of Normal) or greater. It also serves as a predictive method for treating HCC in these patients. He has 1 patent to his name.
Career Highlights
Chang is currently associated with Imclone LLC, where he continues to advance his research and development efforts. His work has the potential to significantly impact the treatment landscape for patients suffering from liver cancer.
Collaborations
Some of his notable coworkers include Paolo B Abada and Yanzhi Hsu, who contribute to the collaborative efforts in research and development at Imclone LLC.
Conclusion
Shao-Chun Chang's innovative work in antibody therapy represents a significant advancement in the fight against hepatocellular carcinoma. His contributions are paving the way for more effective treatments in oncology.